Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report - Takeaways - MDSpire

Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report

  • By

  • Parham Habibzadeh

  • Anushri Kulkarni

  • Drew Hurd

  • Amy Rose

  • Danielle Bednarz

  • Yana G. Najjar

  • John M. Kirkwood

  • Arivarasan Karunamurthy

  • Diwakar Davar

  • July 2, 2026

  • 0 min

Share

  • 1

    Tebentafusp is an ImmTAC targeting gp100 in HLA-A*0201+ patients, showing overall survival benefits in metastatic uveal melanoma.

  • 2

    A patient treated with tebentafusp for over two years achieved durable stable disease but died from sudden cardiac death.

  • 3

    Autopsy revealed extensive tumor necrosis and immune cell infiltration in liver lesions, indicating robust immune activation.

  • 4

    The case highlights the discordance between radiographic assessments and actual tumor response, emphasizing the need for integrated evaluations.

  • 5

    Cardiovascular events in tebentafusp patients, especially those with pre-existing conditions, require careful monitoring and interpretation.

Original Source(s)

Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report

  • by Parham Habibzadeh, Anushri Kulkarni, Drew Hurd, Amy Rose, Danielle Bednarz, Yana G. Najjar, John M. Kirkwood, Arivarasan Karunamurthy, Diwakar Davar

  • July 2, 2026

Related Content

Smartphones Spot Ocular Malignancies

Could a smartphone-based AI system bring ocular oncology screening directly into the patient’s home?

  • July 2, 2026

  • 3 min
Skin cancer risk in alopecia areata: a systematic review and meta-analysis

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy